MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: ASCT
Radiation: yttrium Y 90 ibritumomab tiuxetan
First Posted Date
2008-06-11
Last Posted Date
2018-07-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
122
Registration Number
NCT00695409
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Etoposide
Drug: Irinotecan hydrochloride
First Posted Date
2008-06-09
Last Posted Date
2015-11-20
Lead Sponsor
University of Arizona
Target Recruit Count
31
Registration Number
NCT00693719
Locations
🇺🇸

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Phase 1
Completed
Conditions
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Interventions
Drug: Vorinostat
Drug: Niacinamide
Drug: Etoposide
First Posted Date
2008-06-05
Last Posted Date
2020-11-20
Lead Sponsor
Columbia University
Target Recruit Count
40
Registration Number
NCT00691210
Locations
🇺🇸

Center for Lymphoid Malignancies at CUMC, New York, New York, United States

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Phase 2
Completed
Conditions
Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes
Interventions
Biological: rituximab
Drug: busulfan
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Radiation: total body irradiation (TBI)
Drug: anti-thymocyte globulin IV
First Posted Date
2008-06-05
Last Posted Date
2017-06-28
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
48
Registration Number
NCT00691015
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Pemetrexed
Drug: Cisplatin
Drug: Etoposide
Radiation: Thoracic Radiation Therapy (TRT)
Drug: Vinorelbine
Drug: Paclitaxel
Drug: Carboplatin
First Posted Date
2008-05-30
Last Posted Date
2016-06-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
598
Registration Number
NCT00686959
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

First Posted Date
2008-05-15
Last Posted Date
2024-05-08
Lead Sponsor
University College, London
Target Recruit Count
1202
Registration Number
NCT00678327
Locations
🇬🇧

Southampton General Hospital, Southampton, England, United Kingdom

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Phase 2
Conditions
Lymphoma
Small Intestine Cancer
First Posted Date
2008-05-01
Last Posted Date
2013-08-26
Lead Sponsor
Cancer Research UK
Target Recruit Count
60
Registration Number
NCT00669812
Locations
🇬🇧

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Phase 2
Completed
Conditions
Malignant Fibrous Histiocytoma (MFH) of Bone
Osteosarcoma
Interventions
Biological: Bevacizumab
Drug: Cisplatin
Drug: Doxorubicin
Drug: Methotrexate
Procedure: Surgery
Drug: Ifosfamide
Drug: etoposide
Radiation: Radiotherapy
First Posted Date
2008-04-28
Last Posted Date
2023-08-07
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
43
Registration Number
NCT00667342
Locations
🇺🇸

Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

NCI/NIH - Pediatric Oncology Branch, Bethesda, Maryland, United States

and more 2 locations

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

First Posted Date
2008-04-25
Last Posted Date
2014-12-04
Lead Sponsor
University College, London
Target Recruit Count
47
Registration Number
NCT00666484
Locations
🇬🇧

University College Hospital - London, London, England, United Kingdom

🇬🇧

Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

🇬🇧

King's College Hospital, London, England, United Kingdom

and more 2 locations

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)
Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myelomonocytic Leukemia (M4)
Childhood Acute Eosinophilic Leukemia
Childhood Acute Erythroleukemia (M6)
Interventions
Drug: idarubicin
Drug: cytarabine
Drug: bortezomib
Drug: etoposide
Other: laboratory biomarker analysis
First Posted Date
2008-04-25
Last Posted Date
2018-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
52
Registration Number
NCT00666588
Locations
🇺🇸

Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 79 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy